Keywords: Isis Pharma, Genzyme, Sanofi, Kynamro, Milestone, HoFH, Hypercholesterolemia

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

Article | 31 May 2012

Print This

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen sodium), under development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in